phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: the Japan Breast Cancer Research Group-M05 (PRECIOUS...
[14]Lara PN, Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu–positive non–small-cell lung cancer: a California cancer consortium screening and Phase II trial[J]. Clin Lung Cancer. 2004;5(4):231–236. [15]Mazier...
6.Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742...
phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: the Japan Breast Cancer Research Group-M05 (PRECIOUS) study. Cancer Res 2021;81(4 suppl). ...
19、Shanu Modi,et al.Trastuzumab deruxtecan(T-DXd)vs treatment of physician’s choice(TPC)in patients(pts)with HER2-low,hormone receptor-positive(HR+)unresectable and/or metastatic breastcancer(mBC):Exploratory biomarker analysis of DESTINY-Breast04.2023 ASCO Abstract1020. ...
在发现了neu之后,Weinberg教授并没有太在意它,当时,他的团队在努力攻坚RAS基因的克隆。这给了其他人一个机会,没过两年,就有几个不同团队的研究人员成功克隆出了HER2,测出了完整的序列,并确定了它位于17号染色体上[3,4,5]。 1987年,这也是乳腺癌治疗史上里程碑式的一年,加州大学洛杉矶分校的Dennis Slamon博士联...
1982 年,Robert Weinberg 团队从老鼠的神经母细胞瘤分离出一种致癌基因、命名为「neu 基因」。1985 年,Arthur Levinson 团队在人类基因组 DNA 库中找到了 neu 的人类同源基因,与另一个人类表皮生长因子受体基因 HER 一致,为有所区分,团队把新发现的基因重新命名为 HER2[1]。
HER2是一种受体酪氨酸蛋白激酶,由人HER2/neu基因编码。该癌基因的扩增或过表达通过诱导下游通路,如PI3K/Akt,在乳腺癌发生、发展中起着至关重要的作用。抗HER2药物通过与癌细胞表面表达的HER2蛋白结合发挥作用。HER2阳性乳腺癌既往预后较差,但抗HER2靶向治疗药物显著改善了患者结局。根据美国临床肿瘤学会和美国病理学家学...
Janjigian在Nature上发表题为The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer 的文章,招募了434位HER2呈阳性,并患有胃肠道恶性肿瘤的病人,以随机双盲原则,进行PD-1抗体药物与曲妥珠单抗和化疗联合用药(clinicaltrials.gov, NCT03615326),并发现此种干预方式相比较传统的...
[6]Lara PN Jr, Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan;5(...